Charles B. Huggins. Despite regressions of great magnitude, it is obvious that there are many failures of endocrine therapy to control the disease.

Size: px
Start display at page:

Download "Charles B. Huggins. Despite regressions of great magnitude, it is obvious that there are many failures of endocrine therapy to control the disease."

Transcription

1 New Concepts in ADT Leonard G. Gomella, MD Chairman, Department of Urology President Society of Urologic Oncology Sidney Kimmel Cancer Center Thomas Jefferson University Hospital

2 Charles B. Huggins Nobel Prize winner who established the fact that prostate cancer could be treated by hormonal treatment in the 1940 s He also alluded to what we now call Castration Resistant Prostate Cancer (CRPC) Despite regressions of great magnitude, it is obvious that there are many failures of endocrine therapy to control the disease. Nobel Lecture December 13, 1966 Huggins, 1966.

3 The ADT Con*nuum in Advanced Prostate Cancer Start of ADT LHRH agonist/ antagonist If PSA rising check testosterone Low PSA, low testosterone, no symptoms (GOOD!!) Add an*- androgen pill If testosterone not very low consider changing LHRH agent Stay on therapy Good response Stay on therapy Con*nued rising PSA Other Second line therapy PSA rising with low testosterone: CRPC (castrate resistant prostate cancer) Advanced Therapy for CRPC: Chemo Provenge Xtandi Xofigo Zy*ga ADT is con*nued to keep testosterone as low as possible throughout

4 CRPC Prostate Cancer: Adapting to Castrate Environment Hormone Therapy selective pressure AR AC P Sumo CoACT T MUTATION gain of function Crosstalk AR Sig Path Post-translational Modifications of AR AR SPLICE VARIANTS COFACTOR PERTURBATION CoAct gain CoR loss/ dismissal INTRACRINE ANDROGEN SYNTHESIS Amplification\ Overexpression AR Alterations of Steroid Transporters adaptation RESTORED AR ACTIVITY (rising PSA) RECURRENT TUMOR DEVELOPMENT CRPC Knudsen KE, et al. Trends Endocrinol Metab. 2010;21(5):

5 Sources of Androgen Production Androgens are produced at 3 sites: - Testes - Adrenal gland - Prostate tumor cells (NEW DISCOVERY!)

6 Sources of Androgen Production LHRH Agents Anti-Androgens Androgen pathway blockers help block here

7 New Treatment for CRPC Based on Translational Discoveries PC responds to castration by synthesizing androgens from weaker androgens and/or cholesterol Androgen receptor (AR) responds to castration with molecular and biochemical alterations that cause hypersensitivity to low levels of androgens Progressing PC with low/castrate levels of testosterone is STILL sensitive to androgens ADT STILL A CORE PRINCIPLE

8 SHOULD WE BE USING THE TERM TERTIARY HORMONAL THERAPY BASED ON NEW ANDROGEN RECEPTOR PATHWAY AGENTS?

9 The ADT Con*nuum in Advanced Prostate Cancer Start of ADT LHRH agonist/ antagonist Good response Stay on theray Secondary Hormone Therapy Non Hormonal for CRPC: Chemo Provenge Xofigo Ter9ary CRPC Hormonal Therapy Abiraterone Enzalutamide ADT is con*nued to keep testosterone as low as possible throughout

10 New Concepts in ADT NEWER ARS AGENTS FOR CRPC Abiraterone acetate APPROVED Enzalutamide APPROVED Investigational PREVENT/LIMIT CRPC Intermittent Hormonal Therapy Bipolar Androgen Therapy OPTIMIZE CHOICE OF ADT ARV-7 HSD3B1 gene

11 Newer AR-Pathway Agents APPROVED Abiraterone acetate (approval 2011, 2012) Enzalutamide (approval 2012, 2014) INVESTIGATIONAL TAK700 (development ended) TOK001 (galeterone, multifunctional ARB) ARN 509 (Apalutamide) (ARB) ODM-201 (ARB plus mutant AR) others

12 Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic International Journal of Urology Volume 23, Issue 8, pages , 14 JUN 2016 DOI: /iju

13 European Urology, Volume 67 Issue 3, March

14 1 Dramatic Androgen Reductions With Abiraterone ng/dl Start of treatment Lower limit of sensitivity 10 Testosterone (by LC-MS/MS) 20 Days No rise at progression At progression nmol/l Start of treatment Androstenedione Days No rise at progression At progression DHEA Estradiol nmol/l No rise at progression ρmol/l Start of treatment At progression Days Days post treatment Data on file.

15 Enzalutamide T 1 Inhibits Binding of Androgens to AR T AR 1Enzalutamide inhibits AR testosterone binding 2 cytoplasm Inhibits Nuclear Translocation of AR 2 Enzalutamide receptor inhibi*on blocks the ac*va*onal change induced by AR testosterone binding 3 nucleus Inhibits Inhibits Association Association Of Of AR AR with with DNA DNA AR 3 Enzalutamide inhibits AR testosterone nuclear transloca*on and DNA transcrip*on

16 Peer CME.com 2/3/2016

17 Phase 2 Trial of Galeterone in the Treatment of CRPC (ARMOR2)

18 ClinicalTrials.gov Iden*fier: NCT

19 ARN-509 Apalutamide Next-generation AR inhibitor Phase II - 47 patients CRPC M1 Recommended dose = 240 mg/d Fatigue grade 3 (2%) GI grade 1-2 No epilepsy reported PSA Response (decrease >50%) % Variation PSA weeks 24 weeks Smith MR, et al. J Clin Oncol. 2013;31(Suppl 6): Abstract 7.

20 A Study of Apalutamide (ARN- 509) in Men With Non- Metasta*c Castra*on- Resistant Prostate Cancer (SPARTAN) ClinicalTrials.gov Iden*fier: NCT

21 ODM-201 Has a Unique Profile for ODM-201 enzalutamide 19%* ODM main metabolite 3% ** ARN %* Compound AR affinity Ki (nm) Antagonism WT AR IC50 (nm) Proliferation VCaP IC50 (nm) enzalutamide ARN ODM *Clegg et al, Cancer Research 2012; Forster at al,, Prostate 2011 ** Rat autoradiography (QWBA) confirms brain/plasma ratio of 14C-ODM-201 related radioactivity was , indicating negligible penetration to the brain ORM (main metabolite) No CYP inhibition or induction with therapeutic doses Fizazi K, et al. Eur J Cancer. 2013;49(Suppl 2): Abstract E

22 Efficacy and Safety Study of BAY (ODM- 201) in Men With High- risk Non- metasta*c Castra*on- resistant Prostate Cancer (ARAMIS) ClinicalTrials.gov Iden*fier: NCT

23

24 New Concepts in ADT NEWER ARS AGENTS FOR CRPC Abiraterone acetate APPROVED Enzalutamide APPROVED Investigational PREVENT/LIMIT CRPC Intermittent Hormonal Therapy Bipolar Androgen Therapy OPTIMIZE CHOICE OF ADT ARV-7 HSD3B1 gene

25 What about new data in IHT?

26 What we have learned about IHT Level I evidence supports the oncologic equivalence of IHT compared with continuous androgen blockade in men with biochemical failure. Compared with CHT, IHT demonstrates improved QOL and fewer side effects. Patient selection for IHT is important to maintain good oncologic results. Monitoring of PSA response and duration of offtreatment intervals allow for stratification of patients by risk of progression. Klotz and Toren Current Oncology 19:2012

27 What we have learned about IHT Both SWOG 9346 and PR7 were non-inferiority trials. The non-inferiority result of the PR7 trial showed < 8% survival difference The SWOG 9346 produced an statistically inconclusive result (HR: 1.1; CI: ), with the upper limit being above the pre-specified 90% upper limit of 1.2. Other Benefits: Bone protection, protection against metabolic syndrome, decrease in treatment costs. EAU Prostate cancer guidelines 2012

28 After Dason S., et al CJU February 2014

29 2015 IHT Major Review References: 10,510 Published: 2000 to articles from15 trials (6856 patients) No significant difference between IHT and CHT overall survival cancer-specific survival progression-free survival Minimal difference in self-reported QOL Most trials observed improved physical and sexual functioning with IHT JAMAOncol.2015;1(9):

30 JAMAOncol.2015;1(9):

31 EAU-Guidelines Intermittent Androgen Blockade The best population to consider for IAD has still to be fully characterized. However, the most important factor seems to be the patient s response to the first cycle of IAD, e.g. the PSA level response.... should be the standard of care for those relapsing after radiotherapy Heidenreich A.et al : European Urology 53 (

32 Metastatic Prostate Cancer: CHT versus IHT EAU Is now positive on IHT Ø Not investigational despite empirical cut points IHT used only with castration agents; motivated pt LHRH antagonists might be valid ; CAB is standard Initial induction must be at least 6-7 months IHT ok if PSA<4 in metastatic Defined threshold for re-start: for metastatic Strict follow up every 3-6 months, T/PSA same lab

33 Metastatic Prostate Cancer: CCHT versus IHT ESMO Mixed Ø Continuous ADT is recommended as first-line treatment of metastatic, hormone-naïve disease Ø IHT recommended for men with biochemical relapse after radical RT starting ADT

34 Metastatic Prostate Cancer: CHT versus IHT NCCN positive Ø Can consider for M0/M1 to reduce toxicity (NEW) Ø 3 meta analysis failed to show any survival difference Ø IHT not inferior Ø Study demonstrating increased death in IHT balanced by more non prostate cancer deaths in CHT arm Ø Unplanned analysis Gl 8-10 longer OS with CHT (8y vs 6.8y): Consider CHT Ø QOL better with IHT

35 NCCN 2016 IHT Strategy Ø Initial Induction with standard ADT for 7 mos Ø Risk Stratify based on Serum PSA after 7 mos Low =PSA <0.2ng/ml (Med survival =75mos.) Intermed= PSA ng/ml (Med survival=44 mos) High = PSA>4ng/ml (Med survival =13 mos) Ø Asymptomatic patients after 7 mos of ADT Remain on CAB Ø Symptoms related to ADT Low-Intermediate risk-consider IAD

36 IHT: 2016 Bottom Line Individual studies can be confusing Option after RT failure Option in selected M1 patients after ADT induction (good PSA response) Use in M0 less clear but accepted No data yet on IHT after up front chemo (CHARRTED Trial) Comprehensive metaanalysis of 15 trials No difference in OS/CSS/PFS QOL may be better

37 Introducing Bipolar Androgen Therapy Rapid cycling from supraphysiologic to near-castrate serum T: bipolar androgen therapy (BAT). 16 CRPC: testosterone cypionate (400 mg IM); day 1 of 28) and etoposide (100 mg/d; days 1-14 After three cycles, those with a declining PSA continued on IHT (monotherapy). 4 men > 1 year therapy 10/10 had PSA reductions w/iht after BAT BAT may restore sensitivity to ADTs Sci Transl Med 7 January 2015 Vol. 7, Issue 269, p. 269ra2

38 Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study The primary endpoint met, with 17/29 men (59%, PSA <4 ng/ml at 18 months. Improved QOL The Prostate 76: (2016)

39 New Concepts in ADT NEWER ARS AGENTS FOR CRPC Abiraterone acetate APPROVED Enzalutamide APPROVED Investigational PREVENT/LIMIT CRPC Intermittent Hormonal Therapy Bipolar Androgen Therapy OPTIMIZE CHOICE OF ADT ARV-7 HSD3B1 gene

40 AR targeted therapies in castration-resistant prostate cancer: Bench to clinic International Journal of Urology Volume 23, Issue 8, pages , 14 JUN 2016 DOI: /iju.13137

41 Molecular Profiling Precision/Personalized Therapy AR-V7: an androgen receptor splice variant expressed about 20-fold higher in patients with CRPC If present, may indicate resistance to abiraterone or enzalutamide May allow more targeted therapies Antonarakis ES, et al. J Clin Oncol. 2014;32(5s): Abstract Antonarakis ES, et al. N Engl J Med. 2014;371(11):

42 Progression-Free Survival (Enzalutamide) HR = 8,5 (95% CI: ) Antonarakis E et al. N Engl J Med. 2014;371(11):

43 Progression-Free Survival (Abiraterone) HR = 16.5 (95% CI: ) Antonarakis E et al. N Engl J Med. 2014;371(11):

44 Outcomes: AR-V7 Conversions Outcome AR- V7(- ) AR- V7(- ) (n=36) AR- V7(- ) AR- V7(+) (n=6) AR- V7(+) AR- V7(+) (n=16) PSA response 68% (95% CI, 52-81%) 17% (95% CI, 4-58%) 0% (95% CI, 0-19%) PSA progression- free survival 6.1 months (95% CI, 5.9 mo- NR) 3.0 months (95% CI, 2.3 mo- NR) 1.4 months (95% CI, 0.9 mo- 2.6 mo) Progression- free survival 6.5 months (95% CI, 6.1 mo- NR) 3.2 months (95% CI, 3.1 mo- NR) 2.1 months (95% CI, 1.9 mo- 3.1 mo) Antonarakis E et al. N Engl J Med. 2014;371(11):

45 Implications CRPC patients with detectable AR-V7 in CTCs could be steered away from receiving AR-targeting drugs and could be offered alternative treatments New availability of a blood-based biomarker for AR-V7 detection could allow development of novel ARN-terminal domain inhibitors Antonarakis E et al. N Engl J Med. 2014;371(11):

46 New Genomic ADT Predictor HSD3B1 gene involved in DHT metabolism Inheritance of the HSD3B1 variant allele associated with resistance to ADT When abnormal, the gene causes prostate cancer cells to generate more self androgens when treated with ADT An inherited variant in the HSD3B1 gene may indicate which who benefits from ADT or not Homozygous variant (fast enzyme) have the worst outcomes and men who are homozygous wild-type (slow enzyme) to have the best outcomes, with heterozygotes potentially having an intermediate course August Hearn, et al. Lancet Oncology. In press.

47 Overall Survival According to HSD3B1 Genotype year OS wt/wt 82% wt/mt 74% mt/mt 58% 10 year OS wt/wt 55% wt/mt 35% mt/mt 0% Overall Survival (%) Homozygous Wild-Type 20 Heterozygous 0 P=0.006 Homozygous Variant No. at Risk Wild-Type Heterozygous Homozygous Variant Nima Sharifi Years Hearn, et al. Lancet Oncology. In press.

48 Mayo Clinic Cohort (with Manish Kohli and Don Tindall) Homozygous wild-type: median 1.8 years Heterozygous: median 1.4 years Homozygous variant: median 0.8 years P=0.049 P = Nima Sharifi Hearn, et al. Lancet Oncology. In press.

49 Adult Scrabble... Rearrange the letters to spell out an important part of the human body which is even more useful when erect. P N E S I If you said SPINE you are correct

50

51

52 ODM-201 (AR Inhibitor) Phase I: PSA Response By Dose By Prior Chemotherapy 100 mg 200 mg 300 mg 500 mg P 700 mg o P o s t A B I s t A B I No chemotherapy Chemotherapy Fizazi K, et al. Lancet Oncol. 2014;15(9):

53 ODM-201: Phase II PSA Response at 12 Weeks Chemo-/ CYP17i-naïve Post-chemo/ CYP17i-naive Post-CYP17i Response rate in 65% of patients Response rate 86% at 700 mg bid Response rate in 32% of patients 30% response rate in 20% of patients *Data truncated at +25% Fizazi K, et al. Lancet Oncol. 2014;15(9):

54

55

56

57

58

59

60

61 SKCC Multidisciplinary Approach to Prostate Cancer Care Gomella LG, et al. J Oncology Pract. 2010;6(6):e5-e10.

62 Conclusions Many new oral androgen-receptor based therapies have shown survival benefits in prostate cancer Well tolerated and may be applied to a wide variety of patients An understanding of the FDA approval and patient eligibility criteria critical to their appropriate use Sequencing will take several years to establish The diverse mechanisms of action of all the new CRPC therapies allow for significant patient selection and clinician input on treatment choice Coordination of care essential to optimize outcomes

63 Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic International Journal of Urology Volume 23, Issue 8, pages , 14 JUN 2016 DOI: /iju

64 Endocr Relat Cancer Aug 31

Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Queen Elizabeth Hospital, Birmingham, United Kingdom

Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Queen Elizabeth Hospital, Birmingham, United Kingdom An open-label, phase I/II safety, pharmacokinetic, and proof-of concept study of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (CRPC) K Fizazi 1, P Bono 2, R J Jones

More information

Hormone therapy works best when combined with radiation for locally advanced prostate cancer

Hormone therapy works best when combined with radiation for locally advanced prostate cancer Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients

More information

Updates in Prostate Cancer Treatment 2018

Updates in Prostate Cancer Treatment 2018 Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant

More information

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease

More information

Perspective on endocrine and chemotherapy agents. Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy

Perspective on endocrine and chemotherapy agents. Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr. Sternberg has received research funding for

More information

Initial Hormone Therapy

Initial Hormone Therapy Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA

More information

What will change for men with advanced prostate cancer in the next 24 months? ESO Observatory: Perspective on endocrine and chemotherapy agents

What will change for men with advanced prostate cancer in the next 24 months? ESO Observatory: Perspective on endocrine and chemotherapy agents Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr.Sternberg has received research funding for

More information

www.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)

More information

Initial Hormone Therapy

Initial Hormone Therapy Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA

More information

Secondary Hormonal therapies in mcrpc

Secondary Hormonal therapies in mcrpc Secondary Hormonal therapies in mcrpc Ravindran Kanesvaran Consultant,Division of Medical Oncology National Cancer Centre Singapore 1 Disclosures Research Support/P.I. Sanofi Consultant Major Stockholder

More information

SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia

SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract

More information

PROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute

PROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis

More information

New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일

New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 Castrate-Resistant Prostate Cancer (CRPC) Current standard therapy Androgen receptor (AR) in CRPC New systemic therapies Hormonal therapy

More information

Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy

Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS

More information

Management of Incurable Prostate Cancer in 2014

Management of Incurable Prostate Cancer in 2014 Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis

More information

Have we optimized the use of Androgen Receptor pathway targeted drugs in Castrate-Resistant Prostate Cancer?

Have we optimized the use of Androgen Receptor pathway targeted drugs in Castrate-Resistant Prostate Cancer? Have we optimized the use of Androgen Receptor pathway targeted drugs in Castrate-Resistant Prostate Cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to

More information

Second line hormone therapies. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017

Second line hormone therapies. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Second line hormone therapies Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers

More information

Hormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering

Hormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering > Hormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific

More information

Chemohormonal Therapy For Prostate Cancer. What is old, is new again!

Chemohormonal Therapy For Prostate Cancer. What is old, is new again! Chemohormonal Therapy For Prostate Cancer What is old, is new again! Mount Tremblant January 20, 2017 Kala S. Sridhar MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital Head, GU Medical Oncology

More information

Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC)

Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Amit Bahl Consultant Oncologist Bristol Cancer Institute Clinical Director Spire Specialist Care Centre UK Disclosures Advisory

More information

METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /

METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin

More information

Novel treatment for castration-resistant prostate cancer

Novel treatment for castration-resistant prostate cancer Novel treatment for castration-resistant prostate cancer Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Treatment options for patients

More information

Anti-Androgen Therapies for Prostate Cancer: A Focused Review

Anti-Androgen Therapies for Prostate Cancer: A Focused Review Anti-Androgen Therapies for Prostate Cancer: A Focused Review Nischala Ammannagari, MD, and Saby George, MD, FACP Abstract Among men in the United States, prostate cancer is the most common malignancy

More information

Management of castrate resistant disease: after first line hormone therapy fails

Management of castrate resistant disease: after first line hormone therapy fails Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support

More information

Initial hormone therapy (and more) for metastatic prostate cancer

Initial hormone therapy (and more) for metastatic prostate cancer Initial hormone therapy (and more) for metastatic prostate cancer Silke Gillessen, MD Medical Oncology Kantonsspital St.Gallen Switzerland silke.gillessen@kssg.ch Conflicts of interest Speakers Bureau

More information

Advanced Prostate Cancer. November Jose W. Avitia, M.D

Advanced Prostate Cancer. November Jose W. Avitia, M.D Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000

More information

Evolution or revolution in the treatment of prostate cancer

Evolution or revolution in the treatment of prostate cancer Evolution or revolution in the treatment of prostate cancer de Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Professor of Experimental Cancer Medicine Department of Medicine/ Drug Development Unit

More information

Androgens and prostate cancer: insights from abiraterone acetate and other novel agents

Androgens and prostate cancer: insights from abiraterone acetate and other novel agents Androgens and prostate cancer: insights from abiraterone acetate and other novel agents Ian Davis Ludwig Institute for Cancer Research Austin Health, Melbourne, Australia Supported in part by an Australian

More information

Patients Living Longer: The Promise of Newer Therapies

Patients Living Longer: The Promise of Newer Therapies Patients Living Longer: The Promise of Newer Therapies David M. Nanus, MD! Chief, Division of Hematology and Medical Oncology! Weill Cornell Medicine! New York Presbyterian Hospital!! Demographics 180,890

More information

Timing of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model

Timing of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted

More information

Management of Prostate Cancer

Management of Prostate Cancer Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and

More information

VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE

VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA

More information

UPDATE ON RECENT CUTTING-EDGE TRIALS: TREATMENTS NOW AVAILABLE FOR NEWLY DIAGNOSED mhspc PATIENTS

UPDATE ON RECENT CUTTING-EDGE TRIALS: TREATMENTS NOW AVAILABLE FOR NEWLY DIAGNOSED mhspc PATIENTS UPDATE ON RECENT CUTTING-EDGE TRIALS: TREATMENTS NOW AVAILABLE FOR NEWLY DIAGNOSED mhspc PATIENTS Dr. Neal Shore, Carolina Urologic Research Centre, USA Assoc. Prof. Neeraj Agarwal, Huntsman Cancer Institute,

More information

Androgen deprivation therapy: New concepts. Laurence Klotz Professor of Surgery Sunnybrook HSC University of Toronto

Androgen deprivation therapy: New concepts. Laurence Klotz Professor of Surgery Sunnybrook HSC University of Toronto Androgen deprivation therapy: New concepts Laurence Klotz Professor of Surgery Sunnybrook HSC University of Toronto Clinical Research funding: 1. Bayer/Algeta 2. Ferring 3. Abbott 4. GSK 5. EMD Serono

More information

This article is authors accepted manuscripts in Asian Journal of Andrology.

This article is authors accepted manuscripts in Asian Journal of Andrology. This article is authors accepted manuscripts in Asian Journal of Andrology. OnlineFirst Author s accepted Manuscripts are PDF versions of manuscripts that have been peer reviewed and accepted for publication,

More information

Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer. Michal Mego

Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer. Michal Mego National Cancer Institute, Slovakia Translational Research Unit Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer Michal Mego 2 nd Department of Oncology, Faculty

More information

Advanced Prostate Cancer

Advanced Prostate Cancer Advanced Prostate Cancer SAMO Masterclass 4 th March 2016 Aurelius Omlin Conflicts of interest Advisory Rolle: Astra Zeneca, Astellas, Bayer, Janssen, Pfizer, Sanofi Aventis Research support: TEVA, Janssen

More information

Prostate cancer update: Dr Robert Huddart Cancer Clinic London

Prostate cancer update: Dr Robert Huddart Cancer Clinic London Prostate cancer update: 2013 Dr Robert Huddart Cancer Clinic London Recent developments Improved imaging New radiotherapy technologies Radiotherapy for advanced disease Intermittent hormone therapy New

More information

Developmental Therapeutics for Genitourinary Malignancies

Developmental Therapeutics for Genitourinary Malignancies Developmental Therapeutics for Genitourinary Malignancies Russell Szmulewitz, MD April 2018 Disclosure Information 23 rd Annual Developmental Therapeutics Symposium Name of Speaker I have the following

More information

LUNCH AND LEARN. April 17, 2018 David R. Wilkinson M.D. Gulfshore Urology

LUNCH AND LEARN. April 17, 2018 David R. Wilkinson M.D. Gulfshore Urology LUNCH AND LEARN April 17, 2018 David R. Wilkinson M.D. Gulfshore Urology Medical Therapy for Prostate Cancer Androgen (testosterone) is required for the growth of both normal prostate and prostate cancers

More information

SOGUG meeting New drugs after docetaxel chemotherapy in patient with mcrpc

SOGUG meeting New drugs after docetaxel chemotherapy in patient with mcrpc SOGUG meeting New drugs after docetaxel chemotherapy in patient with mcrpc Stéphane OUDARD, MD, PhD Head of the Oncology department Georges Pompidou Hospital, Paris France University Rene Descartes, Paris

More information

Advanced Prostate Cancer

Advanced Prostate Cancer Advanced Prostate Cancer January 13, 2017 Sindu Kanjeekal MD FRCPC Medical Oncology and Hematology Regional Systemic Quality Lead Erie St Clair Adjunct Professor Schulich School of Medicine and University

More information

Prostate Cancer. Dr. Andres Wiernik 2017

Prostate Cancer. Dr. Andres Wiernik 2017 Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most

More information

Optimizing Outcomes in Advanced Prostate Cancer

Optimizing Outcomes in Advanced Prostate Cancer Optimizing Outcomes in Advanced Prostate Cancer Module 3: Focus on Recent CRPC Guidelines and Advanced Hormone-Sensitive Disease Sébastien J. Hotte, MD, MSc (HRM), FRCPC Medical Oncologist and Head, Phase

More information

Prostate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone

Prostate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal

More information

Modern Screening and Treatment of Advanced Prostate Cancer John Tuckey

Modern Screening and Treatment of Advanced Prostate Cancer John Tuckey Modern Screening and Treatment of Advanced Prostate Cancer John Tuckey Commonest male cancer - 2939 per year Third male cancer death 670 per year More die with it than of it but More people die of prostate

More information

Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes

Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes E. David Crawford, M.D. Professor of Surgery/ Urology/ Radiation Oncology University of Colorado Greetings from Colorado Disclosures Consultant:

More information

Non metastatic castrate-resistant prostate cancer (M0 CRPC) Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France

Non metastatic castrate-resistant prostate cancer (M0 CRPC) Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Non metastatic castrate-resistant prostate cancer (M0 CRPC) Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium for: Amgen, Astellas,

More information

ADT vs chemo + ADT as initial treatment for advanced prostate cancer

ADT vs chemo + ADT as initial treatment for advanced prostate cancer ADT vs chemo + ADT as initial treatment for advanced prostate cancer By Hussein Khaled Prof. Medical Oncology Cairo University Possible Levels of Prostate Cancer At Diagnosis Local-Regional Disease Spread

More information

R&D Presentation for Investors after FY2016

R&D Presentation for Investors after FY2016 R&D Presentation for Investors after FY2016 Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts

More information

Current role of chemotherapy in hormone-naïve patients Elena Castro

Current role of chemotherapy in hormone-naïve patients Elena Castro Current role of chemotherapy in hormone-naïve patients Elena Castro Spanish National Cancer Research Centre Lugano, 17 October 2017 Siegel, Ca Cancer J Clin,2017 Buzzoni, Eur Urol, 2015 -Aprox 15-20% of

More information

STAMPEDE trial (MRC PR08): Arm J overview. Enzalutamide and abiraterone comparison and trial update

STAMPEDE trial (MRC PR08): Arm J overview. Enzalutamide and abiraterone comparison and trial update STAMPEDE trial (MRC PR08): Arm J overview Enzalutamide and abiraterone comparison and trial update Arm J Hypotheses and rationale STAMPEDE: Hypothesis Will addition of enzalutamide and abiraterone to standard-of-care

More information

2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC

2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC Ronald de Wit Erasmus MC Cancer Institute The Netherlands 2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC Disclosures Sanofi ; research grant support, consultancy and speaker fees Astellas;

More information

When exogenous testosterone therapy is. adverse responses can be induced.

When exogenous testosterone therapy is. adverse responses can be induced. Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release

More information

Metastatic prostate carcinoma. Lee Say Bob July 2017

Metastatic prostate carcinoma. Lee Say Bob July 2017 Metastatic prostate carcinoma Lee Say Bob July 2017 Scenario A 58 year old gentleman presents with PSA 200 ng/ml with hard prostate and bone mets. LUTS but upper tracts are normal with normal RP. history

More information

New Treatment Options for Prostate Cancer

New Treatment Options for Prostate Cancer New Treatment Options for Prostate Cancer Moderator: Jeremy P. Goldberg, President, JPG Healthcare LLC Panelists: Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana- Farber Cancer

More information

SIMPOSIO. Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico

SIMPOSIO. Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico SIMPOSIO Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico Definition of Oligometastatic PCa 1-3 synchronous metastases (bone and/or lymph nodes) 2-5 synchronous metastases

More information

Prostate Cancer Management: From Early Chemical Recurrence to HRPC (excluding Immunotherapy).

Prostate Cancer Management: From Early Chemical Recurrence to HRPC (excluding Immunotherapy). Thanks to: The Medical Educator Consortium Luis Raez, MD, Florida International University 15th ed. Prostate Cancer Management: From Early Chemical Recurrence to HRPC (excluding Immunotherapy). Mayer Fishman,

More information

Androgen Deprivation Therapy A Question of Timing

Androgen Deprivation Therapy A Question of Timing Androgen Deprivation Therapy A Question of Timing James Johnston BSc MBChB FRACS (Urol) Disclosure 1 OUTLINE History Watchful waiting Node positive patient Recurrence Intermittent Androgen Suppression

More information

Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials

Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials 811450TAU0010.1177/1756287218811450Therapeutic Advances in UrologyVS Koshkin and EJ Small review-article2018 Therapeutic Advances in Urology Review Apalutamide in the treatment of castrate-resistant prostate

More information

ADVANCES IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER. ALICIA K. MORGANS, MD, MPH Associate Professor of Medicine Northwestern University, USA

ADVANCES IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER. ALICIA K. MORGANS, MD, MPH Associate Professor of Medicine Northwestern University, USA ADVANCES IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER ALICIA K. MORGANS, MD, MPH Associate Professor of Medicine Northwestern University, USA MAY 2018 DISCLAIMER Please note: The views expressed within

More information

X, Y and Z of Prostate Cancer

X, Y and Z of Prostate Cancer X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios

More information

Cancer de la prostate métastatique: prise en charge précoce

Cancer de la prostate métastatique: prise en charge précoce Cancer de la prostate métastatique: prise en charge précoce Stéphane Oudard, MD, PhD Georges Pompidou Hospital, Oncology Department, Paris, France stephane.oudard@egp.aphp.fr SAGB.CAB.14.08.0382c 3/02/2016

More information

Early Chemotherapy for Metastatic Prostate Cancer

Early Chemotherapy for Metastatic Prostate Cancer Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,

More information

SUMMARY. 3. Emerging understanding of mechanisms of resistance to current treatments

SUMMARY. 3. Emerging understanding of mechanisms of resistance to current treatments SUMMARY 1. Discuss the active agents in prostate cancer currently available in Australia 2. Celebrate the growing role for Prostate Medical Oncologists in Multi Disc Teams active treaments overall survival

More information

ESMO SUMMIT MIDDLE EAST 2018

ESMO SUMMIT MIDDLE EAST 2018 ESMO SUMMIT MIDDLE EAST 2018 14 Years of progress in Prostate Cancer Standards of Care and new targets Name Ronald de Wit 6-7 April 2018, Dubai, UAE CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche

More information

8/31/ ) Intermittent androgen deprivation in androgen-sensitive PCa. 1) Alpharadin (Ra223) in CRPC with bone metastases

8/31/ ) Intermittent androgen deprivation in androgen-sensitive PCa. 1) Alpharadin (Ra223) in CRPC with bone metastases Bruce J. Roth, M.D. Clinical Trials: Medivation, Oncogenix 1) Alpharadin (Ra223) in CRPC with bone metastases 2) Enzalutamide (MDV-31) in CRPC and prior docetaxel 3) Abiraterone in chemo-naïve CRPC 4)

More information

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after

More information

A Forward Look at Options for. In Prostate Cancer

A Forward Look at Options for. In Prostate Cancer A Forward Look at Options for Prostate Cancer Charles J Ryan, MD Associate Professor of Medicine Helen Diller Family Comprehensive Cancer Center University of California, San Francisco UC 1 SF UC SF Castration

More information

GU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer. Dr. Simon Yu Nov 18, 2017

GU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer. Dr. Simon Yu Nov 18, 2017 GU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer Dr. Simon Yu Nov 18, 2017 Faculty/Presenter Disclosure Faculty: Dr. Simon Yu Relationships with commercial interests: Grants/Research

More information

Figure S1. Figure S2. Figure S3.

Figure S1. Figure S2. Figure S3. Figure S1. PSA expression in VCaP was not dependent on the residual androgens in hormonedepleted medium. VCaP or LNCaP cells grown in CSS medium or SFM (serum-free medium) were treated with ethanol (-)

More information

Management of mcrpc: Hormonal therapy and treatment sequence for CRPC

Management of mcrpc: Hormonal therapy and treatment sequence for CRPC Management of mcrpc: Hormonal therapy and treatment sequence for CRPC Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Credentials

More information

Management of castrate resistant disease; after first line hormone therapy fails

Management of castrate resistant disease; after first line hormone therapy fails Management of castrate resistant disease; after first line hormone therapy fails Dr. Syed A Hussain Clinical Senior Lecturer and Consultant in Medical Oncology University of Liverpool and Clatterbridge

More information

Group Sequential Design: Uses and Abuses

Group Sequential Design: Uses and Abuses Group Sequential Design: Uses and Abuses Susan Halabi Department of Biostatistics and Bioinformatics, Duke University October 23, 2015 susan.halabi@duke.edu What Does Interim Data Say? 2 Group Sequential

More information

Risk of renal side effects with ADT. E. David Crawford University of Colorado, Aurora, CO, USA

Risk of renal side effects with ADT. E. David Crawford University of Colorado, Aurora, CO, USA Risk of renal side effects with ADT E. David Crawford University of Colorado, Aurora, CO, USA ADT: A key treatment for advanced prostate cancer John Hunter 1780-castration 1904: First RP 1938: Acid Phos.

More information

Two late stage clinical programs

Two late stage clinical programs Safe harbor This presentation and our remarks based upon it, including responses to questions made during and following the presentation, may include forward-looking statements. Such statements are subject

More information

ERLEADA (apalutamide) oral tablet

ERLEADA (apalutamide) oral tablet ERLEADA (apalutamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Teply BA, Wang H, Luber B, et al. Bipolar androgen

More information

Philip Kantoff, MD Dana-Farber Cancer Institute

Philip Kantoff, MD Dana-Farber Cancer Institute CHEMOTHERAPY FOR MCRPC Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School 1 Disclosure of Financial Relationships With Any Commercial Interest Name Nature of Financial Commercial Interests

More information

Prostate Cancer in men with germline DNA repair deficiency

Prostate Cancer in men with germline DNA repair deficiency Prostate Cancer in men with germline DNA repair deficiency Bruce Montgomery, MD Professor, Medicine and Urology Univ Washington, Fred Hutchinson CRC VA Puget Sound HCS Disclosures Company Tokai, ESSA,

More information

ASCO 2012 Genitourinary tumors

ASCO 2012 Genitourinary tumors ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase

More information

ESMO SUMMIT AFRICA Practice changing studies in Prostate Cancer in 2016 and 2017 and cost-effectiveness Ronald de Wit

ESMO SUMMIT AFRICA Practice changing studies in Prostate Cancer in 2016 and 2017 and cost-effectiveness Ronald de Wit ESMO SUMMIT AFRICA 2018 Practice changing studies in Prostate Cancer in 2016 and 2017 and cost-effectiveness Ronald de Wit CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche Merck Lilly 14 years of

More information

When exogenous testosterone therapy is. adverse responses can be induced.

When exogenous testosterone therapy is. adverse responses can be induced. Theoretical tips It has been reasoned that discontinuation of ADT in non orchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release

More information

In autopsy, 70% of men >80yr have occult prostate ca

In autopsy, 70% of men >80yr have occult prostate ca Prostate Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Two randomized trials showed survival benefit of adding docetaxol to ADT in fit man with very high localized disease

More information

The Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD

The Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD Februray, 2013 The Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD Why/How my cancer is back after surgery and/or radiation? Undetected micro-metastatic disease (spreading) before local

More information

majority of the patients. And taking an aggregate of all trials, very possibly has a modest effect on improved survival.

majority of the patients. And taking an aggregate of all trials, very possibly has a modest effect on improved survival. Hello. I am Farshid Dayyani. I am Assistant Professor in Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center. We will be talking today about prostate cancer for survivorship

More information

Oligometastasis. Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie?

Oligometastasis. Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie? Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie? Daniel M. Aebersold 09. Dezember 2016 Oligometastasis JCO, 1995 1 Oligometastasis: Chance for

More information

Treatment of Advanced Prostate Cancer

Treatment of Advanced Prostate Cancer Treatment of Advanced Prostate Cancer Wm. Kevin Kelly, DO Associate Professor of Medicine and Surgery Yale University Yale University School of Medicine Advanced Prostate Cancer Metastatic Cancer Prostate

More information

Mapping the Complexity of Androgen Signaling In Prostate Cancer Progression Eleni Efstathiou MD PhD

Mapping the Complexity of Androgen Signaling In Prostate Cancer Progression Eleni Efstathiou MD PhD Mapping the Complexity of Androgen Signaling In Prostate Cancer Progression Eleni Efstathiou MD PhD The University of Athens Medical School Dept of Clinical Therapeutics Prostate Cancer Evolution Chemotherapy

More information

ACK1 Tyrosine Kinases: A Critical Regulator of Prostate Cancer

ACK1 Tyrosine Kinases: A Critical Regulator of Prostate Cancer ACK1 Tyrosine Kinases: A Critical Regulator of Prostate Cancer Nupam Mahajan Moffitt Cancer Center Learners Objectives How Androgen Receptor (AR) signaling is accomplished in absence of androgen What are

More information

Prostate cancer Management of metastatic castration sensitive cancer

Prostate cancer Management of metastatic castration sensitive cancer 18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial

More information

Strategic decisions for systemic treatment. metastatic castration resistant prostate cancer (mcrpc)

Strategic decisions for systemic treatment. metastatic castration resistant prostate cancer (mcrpc) Strategic decisions for systemic treatment metastatic castration resistant prostate cancer (mcrpc) SAMO Luzern 14.09.2012 Richard Cathomas Onkologie Kantonsspital Graubünden richard.cathomas@ksgr.ch mcrpc

More information

Summary A LOOK AT ANTIANDROGEN THERAPIES FOR NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER CASTRATION-RESISTANT PROSTATE CANCER TREATMENT OPTIONS

Summary A LOOK AT ANTIANDROGEN THERAPIES FOR NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER CASTRATION-RESISTANT PROSTATE CANCER TREATMENT OPTIONS A LOOK AT ANTIANDROGEN THERAPIES FOR NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER OCTOBER 2018 Summary CASTRATION-RESISTANT PROSTATE CANCER Prostate cancer is the second most common cause of cancer

More information

Taxanes and New hormonal agents: How they work?

Taxanes and New hormonal agents: How they work? Taxanes and New hormonal agents: How they work? Taxanes Microtubules are highly dynamic cytoskeletal fibres that are composed of tubulin of which are crucial to mitosis and cell division. Jordan Nat Rev

More information

Intermittent Androgen Suppression - A standard of care or a good second choice?

Intermittent Androgen Suppression - A standard of care or a good second choice? Intermittent Androgen Suppression - A standard of care or a good second choice? Dr Nicholas Buchan Uro-oncology Fellow Olympic Medal Standings Gold Silver Bronze USA 9 15 13 Germany 10 13 7 Canada 14 7

More information

Board Review 2017: Prostate Cancer. Dana Rathkopf, MD Associate Attending

Board Review 2017: Prostate Cancer. Dana Rathkopf, MD Associate Attending Board Review 2017: Prostate Cancer Dana Rathkopf, MD Associate Attending www.mskcc.org The Paradox of Prostate Cancer High prevalence in the general population: over diagnosis of clinically insignificant

More information

Metasta&c prostate cancer. Walid Obeid PGY IV SGHUMC

Metasta&c prostate cancer. Walid Obeid PGY IV SGHUMC Metasta&c prostate cancer Walid Obeid PGY IV SGHUMC Defini&on Stage IV prostate cancer : is defined by the American Joint CommiEee on Cancer's TNM classifica&on system: T4, N0, M0, any prostate- specific

More information

Clinical Case Conference

Clinical Case Conference Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3

More information

Incorporating New Agents into the Treatment Paradigm for Prostate Cancer

Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center

More information

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/103187/ This is the author s version of a work that was submitted to / accepted

More information